Buparlisib or placebo, plus paclitaxel, in head and neck carcinoma

• Research type

  Research Study

• Full title

  Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated recurrent or metastatic head and neck squamous cell carcinoma.

• IRAS ID

  135128

• Contact name

  Martin Forster

• Contact email

  martin.forster@cancer.ucl.ac.uk

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2013-000744-26

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  13/SW/0247

• Date of REC Opinion

  1 Oct 2013

• REC opinion

  Favourable Opinion